FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2100-2101 May 13, 2004 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lee, T. H. PubMed Citation

To the Editor: The proliferation of "me-too" drugs leads to beneficial cost reductions, as Lee notes in his Perspective article (Jan. 15 issue),¹ but it may also put patients at risk. Each me-too drug comes to the market with limited clinical experience as compared with compounds already in use. Five me-too drugs in the statin and quinolone classes have been withdrawn or restricted because of serious adverse effects that were not recognized until months or years after their approval (temafloxacin, grepafloxacin, cerivastatin, sparfloxacin, and trovafloxacin).

The potential for cost savings may induce health systems to use a me-too drug before . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.